Arsenic trioxide (As 2 O 3 ) is used clinically to treat acute promyelocytic leukemia but is less successful in other malignancies. To identify targets for potential combination therapies, we have begun to characterize signaling pathways leading to As 2 O 3 -induced cytotoxicity. Previously, we described the requirement for a reactive oxygen species -mediated, SEK1/c-Jun NH 2 -terminal kinase (JNK) pathway to induce apoptosis. AKT inhibits several steps in this pathway; therefore, we postulated that As 2 O 3 might decrease its activity. Indeed, As 2 O 3 decreases not only AKT activity but also total AKT protein, and sensitivity to As 2 O 3 correlates with the degree of AKT protein decrease. Decreased AKT expression further correlates with JNK activation and the release of AKT from the JNKinteracting protein 1 scaffold protein known to assemble the mitogen-activated protein kinase cascade. We found that As 2 O 3 regulates AKT protein stability without significant effects on its transcription or translation. We show that As 2 O 3 decreases AKT protein via caspase-mediated degradation, abrogated by caspase-6, caspase-8, caspase-9, and caspase-3 inhibitors but not proteosome inhibitors. Furthermore, As 2 O 3 enhances the ability of a heat shock protein 90 inhibitor to decrease AKT expression and increase growth inhibition. This suggests that As 2 O 3 may be useful in combination therapies that target AKT pathways or in tumors that have constitutively active AKT expression.
Introduction
Arsenic trioxide (As 2 O 3 ) is an effective treatment for patients with acute promyelocytic leukemia (APL) but has been less successful in other malignancies at tolerable doses. Several groups have begun preclinical and earlystage clinical efforts to develop rational combination therapies that increase the efficiency of As 2 O 3 . Some of these combinations show promise in non-APL acute myelogenous leukemia and multiple myeloma (1 -3) . To further identify therapeutic targets for such combination therapies, we have begun to characterize signaling pathways leading to As 2 O 3 -induced cytotoxicity.
As 2 O 3 initiates many signaling cascades within a cell, but identifying those pathways essential for the induction of apoptosis is critical. As 2 O 3 treatment results in production of reactive oxygen species (ROS) in leukemic cells (4, 5) . Several compounds that enhance ROS production can sensitize cells to As 2 O 3 -induced apoptosis. We have shown that either L-buthionine sulfoximine (BSO; ref. 4) , which depletes glutathione stores, or Trolox (6), a vitamin E analogue that selectively acts as a pro-oxidant in malignant cells (6, 7) , can enhance As 2 O 3 -induced cytotoxicity. In addition, antioxidant compounds such as N-acetylcysteine inhibit As 2 O 3 -induced apoptosis (8) . ROS production by As 2 O 3 is linked to the induction of stress pathways, including mitogen-activated protein kinases (MAPK). As 2 O 3 treatment results in c-Jun NH 2 -terminal kinase (JNK) activation, which is required for maximal induction of apoptosis in several cell types (9) . Genetic deletion of the upstream activator kinase SEK1/MAPK kinase 4 in mouse embryo fibroblasts inhibits both As 2 O 3 -induced JNK activity and apoptosis (9) .
In addition to activated pathways leading to death, we hypothesized that survival signals would be inhibited by As 2 O 3 . AKT, a serine/threonine protein kinase, mediates the cell survival signals coming through phosphoinositide 3-kinase by phosphorylation and inactivation of several proapoptotic proteins, including BAD (10), caspase-9 (11, 12) , and members of the forkhead family of transcription factors (13, 14) , rendering them inactive. AKT also negatively regulates the MAPK pathways required for As 2 O 3 -induced apoptosis. AKT phosphorylates SEK1 on Ser 78 and inhibits its function (15) . AKT also phosphorylates and inactivates ASK1, a MAPK kinase kinase upstream of SEK1 (15, 16) . Oxidative stress initiates the dissociation of AKT from JNK-interacting protein 1 (JIP1), a scaffolding protein, which facilitates the activation of the ASK-SEK-JNK pathway (17) . AKT binding to JIP1 negatively regulates this signal transduction pathway (17) ; thus, a decrease in AKT as a result of oxidative stress could enhance JNK signaling.
Here, we present data showing a correlation between sensitivity to As 2 O 3 -induced death and decreased AKT activity. We further show that As 2 O 3 decreases total AKT protein levels without affecting transcription or translation of AKT. Instead, we found that As 2 O 3 decreased AKT protein expression in a caspase-dependent manner. In addition, we show that As 2 O 3 acts to enhance the growth inhibition seen with the heat shock protein 90 (hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), suggesting possible combination therapies to target AKT pathways.
Materials and Methods
Reagents As 2 O 3 , BSO, anti-h-actin antibody and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent were purchased from Sigma. LY294002, MG132, and caspase inhibitors were purchased from Calbiochem (EMD Biosciences). AKT antibody and the nonradioactive AKT kinase assay kit were purchased from Cell Signaling Technology.
Cell Culture and Treatments NB4 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and penicillin/streptomycin. The arsenic-resistant NB4-MR-AsR2 and AsR3 cell lines (AsR2 and AsR3) were originally derived from the arsenicsensitive NB4 cells and are cultured in the presence of 2 Amol/L As 2 O 3 (4). AsR2 and AsR3 cells were washed thoroughly before all experiments. MDA-MB-468 cells were cultured in a-MEM containing 10% fetal bovine serum. MDA-MB-231 cells were cultured in DMEM/F-12 containing 10% fetal bovine serum. Breast cancer cells were plated at 10 4 per well of a 24-well plate for 3-day growth curve analyses.
Propidium Iodide Staining
Quantitation of apoptotic cells was done as previously described (18) . Cells were washed in 4jC PBS/5% fetal bovine serum/0.01 mol/L NaN 3 , pelleted, and resuspended in 0.5 mL of hypotonic fluorochrome solution containing 50 Ag/mL propidium iodide (Sigma), 0.1% sodium citrate, and 0.1% Triton X-100. Cells undergoing DNA fragmentation and apoptosis were shown to be those in which propidium iodide fluorescence was weaker than the typical G 0 -G 1 cell cycle peak.
AKT Kinase Assay Cells were processed following the protocol from Cell Signaling Technology. Briefly, cells were lysed in 1Â cell lysis buffer and 200 AL of protein extracts were incubated with AKT monoclonal antibody immobilized on agarose beads for 2 h at 4jC. Beads were then washed in 1Â cell lysis buffer and in 1Â kinase buffer. For the kinase assay, beads were resuspended in the 1Â kinase buffer supplemented with 200 Amol/L ATP and glycogen synthase kinase 3a/h (GSK3a/h; Ser 21/9 ) fusion protein and incubated 30 min at 30jC. To stop the reaction, 2Â SDS sample buffer was added to the samples, which were then boiled 5 min and loaded on a 12% SDS-PAGE gel. Samples were analyzed by immunoblotting with a phosphorylated GSK3a/h (Ser 21/9 ) antibody. Anti-AKT immunoblots were done as a control for the immunoprecipitation.
JNK Kinase Assay Assays for JNK activity were done as previously described (9) . Briefly, following treatment, cells were washed and lysed in the presence of phosphatase and Immunoblotting was done before immunoprecipitation to ensure that treatment did not affect absolute JNK1 expression levels.
Protein Extraction and Immunoblotting After treatment, cells were washed with cold PBS and lysed in radioimmunoprecipitation assay buffer [50 mmol/L Tris-HCl (pH 8), 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS] containing protease/phosphatase inhibitors. Protein concentration was measured with 5Â Bradford reagent (Bio-Rad). Proteins were separated by SDS-PAGE gel and then transferred onto a nitrocellulose membrane. Membranes were blocked (1 h, room temperature) in TBS containing 0.1% Tween 20 (TBST) and 5% nonfat milk and incubated with anti-AKT (1:500), anti-JIP1, anti-h-actin, or anti-JNK1 (overnight, 4jC). The next day, membranes were washed in TBST and incubated with horseradish peroxidase -conjugated secondary antibody (1 h, room temperature). Membranes were then washed and peroxidase activity was visualized with the enhanced chemiluminescence method (GE Healthcare Biosciences-Amersham).
Coimmunoprecipitation Assays NB4 cells were lysed in buffer containing 50 mmol/L Tris (pH 8), 150 mmol/L NaCl, and 1% Triton X-100. After preclearing lysates, specific proteins were immunoprecipitated overnight at 4jC with anti-AKT antibody (sc-1618-R). Protein A-agarose beads were added for 4 h and then the beads were washed thrice in lysis buffer. Immunoprecipitates were run on SDS-PAGE gels and immunoblotted as described above.
Transfection Assays Transient transfection of NB4 cells was done by electroporation using the Gene Pulser apparatus (Bio-Rad). For constitutively active AKT transfection, 1 Â 10 7 NB4 cells were transfected by electroporation with 10 Ag of either empty vector pCMV (mock) or a constitutively active AKT (Dr. Adriane Stoica, Georgetown University, Washington, District of Columbia). Cells were treated with 2 Amol/L As 2 O 3 . After 48 h, cell proliferation was assessed by MTT assay.
Proteosome Inhibition Assay NB4 cells were seeded in the presence or absence of 5 Amol/L As 2 O 3 for 18 h. For the last 6 h, MG132, a proteasome inhibitor, was added to some cultures. Cells were then harvested and lysed with radioimmunoprecipitation assay buffer. Immunoblotting analysis was done using an anti-AKT polyclonal antibody (Cell Signaling Technology) and h-actin antibody (Sigma) as a loading control.
Caspase Inhibition Assays NB4 cells were treated with 5 Amol/L As 2 O 3 in the presence or absence of Z-VAD (caspase inhibitor I), a pan-caspase inhibitor (Calbiochem), or with the Caspase Inhibitor Set II from Calbiochem: caspase-1 inhibitor VI (ZYVAD-fmk), caspase-2 inhibitor I (ZVDVAD-fmk), caspase-3 inhibitor II (Z-DEVD-fmk), caspase-5 inhibitor I (Z-WEHD-fmk), caspase-6 inhibitor I (Z-VEID-fmk), caspase-8 inhibitor (Z-IETD-fmk), caspase-9 inhibitor I (Z-LEHD-fmk), and caspase inhibitor III (Boc-D-fmk). After 6 or 24 h, cells were counted and then harvested to prepare whole-cell extracts. Immunoblotting analysis was done to evaluate AKT protein levels.
Caspase-3 Activity Assay Caspase-3 activation was detected using the Caspase-Glo 3/7 Assay (Promega). NB4 and AsR2 cells were treated for 18 h. Subsequently, cells were incubated for 30 min at room temperature with an equal volume of Ac-DEVD-pNA substrate in the buffer provided. The amount of light was measured using a GloMax 20/20 luminometer (Promega) and normalized to cell number.
Results

AKTActivity and Protein Levels Decrease in NB4 Cells following As 2 O 3 Treatment
Based on our previous findings that an intact JNK signaling pathway is required for As 2 O 3 -induced apoptosis, we hypothesized that As 2 O 3 may concomitantly decrease negative regulators of this pathway. We chose to assess AKT expression and activity in our model system of the arsenicsensitive NB4 APL cell line after treatment for increasing amounts of time with 5 Amol/L As 2 O 3 . AKT activity was measured using a nonradioactive kinase assay with GSK3a/ h (Ser 21/9 ) fusion protein as a substrate. Indeed, As 2 O 3 decreases AKT activity within 18 h (Fig. 1A, top) . In addition, we observed a time-dependent decrease in total AKT protein immunoprecipitated (Fig. 1A, bottom) . To verify that this was not an artifact of the kinase assay, we then assessed total AKT levels by immunoblot and found a dose-dependent (Fig. 1B) and time-dependent (Fig. 1C ) decrease in AKT protein levels, confirming our immunoprecipitation results that 5 Amol/L As 2 O 3 decreases AKT by 6 to 8 h. In addition, longer exposures with low concentrations of As 2 O 3 (0.5 Amol/L), well within the clinically achievable range, also decreased AKT protein expression (Fig. 1D) .
The As 2 O 3 -induced decrease in AKT protein levels was not specific to APL cells. In both the IM9 B lymphoblastoid cell line and the HS-Sultan multiple myeloma cell line, As 2 O 3 decreased AKT protein expression in a dosedependent manner after 24 h, which correlated with the ability of As 2 O 3 to activate JNK as assessed by in vitro kinase assay where JNK was immunoprecipitated from cell lysates and used to phosphorylate a glutathione S-transferase-c-Jun construct in vitro (Fig. 2A) . Notably, higher doses of As 2 O 3 were required to initiate the signaling events in these cell lines, which correlates with their decreased sensitivity to As 2 O 3 . A decrease in AKT levels correlated with sensitivity to As 2 O 3 in breast cancer cell lines as well. AKT expression as well as AKT phosphorylation at Ser 473 was decreased in MDA-MB-468 cells (Fig.  2B ), which have a high level of constitutively active AKT. However, MDA-MB-231 cells, which are significantly less sensitive to As 2 O 3 -induced growth inhibition at day 3, did not have a decreased level of AKT after exposure to As 2 O 3 .
As 2 O 3 Decreases AKT Protein Levels in NB4 (ArsenicSensitive APL Cell Line) but not in AsR2 and AsR3 (Arsenic-Resistant APL Cell Lines)
If the arsenic-induced decrease of AKT protein facilitates cell death, we hypothesized that cells resistant to (4) . When NB4 cells as well as the resistant clones AsR2 and AsR3 were treated with 5 Amol/L As 2 O 3 for 24 h, AKT protein expression was decreased in the parental line but not in the resistant clones (Fig. 3A) . Furthermore, when glutathione levels were decreased by a pretreatment with BSO for 18 h followed by 2 Amol/L As 2 O 3 treatment for 24 h, the AKT protein decreased and apoptosis was induced ( Fig. 3B ; data not shown). AKT levels were not affected by treatment with BSO or As 2 O 3 alone in these cell lines. We have previously shown that BSO, which decreases intracellular reduced glutathione levels, can sensitize these arsenic-resistant cells to As 2 O 3 -induced ROS production and apoptosis (4) . Therefore, these data suggest that AKT is downstream of ROS generation by As 2 O 3 .
We then asked if pharmacologic inhibition of AKT in the arsenic-resistant cell lines could sensitize them to As 2 O 3 -induced death. AsR2 cells were treated with 2 Amol/L As 2 O 3 over 2 days in the presence or absence of 2.5 Amol/L LY294002. LY294002 is an inhibitor of phosphoinositide 3-kinase, an activating kinase upstream of AKT. Interestingly, this inhibitor can overcome resistance to As 2 O 3 in the AsR2 cells as assessed in growth curves, propidium iodide staining, and caspase-3 activation (Fig. 3C) . To confirm that AKT down-regulation was necessary for As 2 O 3 -induced death, we asked whether overexpression of AKT in the NB4 cells results in resistance to As 2 O 3 -induced growth inhibition. Indeed, NB4 cells transiently transfected with a constitutively active AKT construct were completely resistant to a dose of As 2 O 3 that substantially inhibited growth in untransfected or vector-transfected cells (Fig. 3D) . Together, these data show that decreased AKT is an essential part of the mechanism of As 2 O 3 -induced apoptosis in APL cells, and resistance to As 2 O 3 is associated with persistent AKT expression.
As 2 O 3 Treatment Decreases AKT-JIP1Association
We then asked how AKT could inhibit As 2 O 3 -induced cell death. We have previously shown that JNK activation is critical for As 2 O 3 -induced apoptosis in NB4 cells. AKT is a negative regulator of this pathway, by binding to JIP1, the scaffold protein that integrates both positive and negative regulators of JNK signaling. When AKT is bound to JIP1, the MAPK cascade cannot assemble and JNK is not activated. AKT and JNK are coordinately and inversely regulated in our model system; therefore, we postulated that inhibition of AKT would increase JNK activation induced by As 2 O 3 . NB4 cells were serum starved for 24 h and subsequently treated for 24 h with 0.5 Amol/L As 2 O 3 in the presence or absence of 2.5 Amol/L LY294002. As we have previously shown, 0.5 Amol/L As 2 O 3 induced JNK activity at this time point (Fig. 4A) . Addition of LY294002 enhanced the JNK activation alone and the combination of these drugs further enhanced JNK activation (Fig. 4A) . These data further correlate decreased AKT activity with JNK activation. Next, we investigated whether As 2 O 3 -induced JNK activity was correlated with a decreased association of AKT with JIP1. Endogenous AKT and JIP1 were coimmunoprecipitated from NB4 cells treated for 24 h with control or 1 to 5 Amol/L of As 2 O 3 . AKT and JIP1 were strongly associated in untreated cells, but this association was significantly decreased even at the lowest dose of As 2 O 3 , which did not decrease AKT protein at this time point (Fig. 4B) , indicating that As 2 O 3 -induced JNK activation correlates with decreased AKT-JIP1 binding. Interestingly, as AKT protein levels are decreasing with As 2 O 3 treatment, JIP1 levels increase.
As 2 O 3 Regulates AKT Protein Levels through a Proteasome-Independent and Caspase-3^Dependent Pathway
We next investigated the mechanism by which As 2 O 3 treatment decreases AKT expression. We found that As 2 O 3 affects neither transcriptional activity of AKT1 as assessed by transient transfection and chromosomal immunoprecipitation assays nor the mRNA stability ( Supplementary  Fig. S1 ).
1 Therefore, we hypothesized that As 2 O 3 induced degradation of AKT protein. AKT degradation has been shown to occur in a proteasome-dependent manner (19, 20) . We treated NB4 cells with 5 Amol/L As 2 O 3 for 18 h. Six hours before harvesting the cells, MG132, a potent reversible cell-permeable proteasome inhibitor, was added. Immunoblotting for total AKT protein levels showed that inhibiting the proteasome pathway could not rescue AKT protein from As 2 O 3 -induced degradation (Fig. 5A ). AKT has also been shown to be a target of caspase-mediated degradation, particularly caspase-3, caspase-6, and caspase-7 (21 -23). To test whether caspases mediate the As 2 O 3 -induced decrease in AKT protein levels, we treated NB4 cells for 6 or 24 h with Z-VAD, a pan-caspase inhibitor, alone or in combination with 5 Amol/L As 2 O 3 . Following Z-VAD treatment, AKT protein levels were protected from As 2 O 3 -induced decrease (Fig. 5B) , suggesting that one or more caspases are involved in As 2 O 3 effect on AKT protein. We then treated NB4 cells with a wide range of caspase inhibitors in combination with As 2 O 3 . Inhibitors of caspase-1, caspase-2, and caspase-5 had no effect on arsenic-induced AKT protein degradation, whereas caspase-3, caspase-6, caspase-8, and caspase-9 could each slightly inhibit As 2 O 3 effect on total AKT protein levels but not as strongly as pan-caspase inhibitors (Z-VAD and Boc-D-fmk; Fig. 5C ). Of the caspases implicated in this inhibitor experiment, caspase-3 is the furthest downstream and likely to integrate all the initiator caspase signals. To correlate caspase-3 activity with sensitivity to As 2 O 3 , we assessed caspase-3 activity in NB4 and AsR2 cells after 18 h of treatment with As 2 O 3 alone or combined with Z-DEVD-fmk (Fig. 5D ). As 2 O 3 alone could increase caspase-3 activity in NB4 cells, which was decreased when As 2 O 3 was used in combination with the caspase-3 -specific inhibitor.
However, in the arsenic-resistant AsR2 cell line, no increase in caspase-3 activity was detected in the presence or absence of As 2 O 3 (Fig. 5D) . Increased caspase-3 activity in the arsenic-sensitive NB4 cells correlates with the ability of As 2 O 3 to decrease AKT protein levels.
As 2 O 3 Enhances the Cytotoxic Effects of 17-AAG 17-AAG is a geldanamycin derivative currently undergoing clinical development, which binds to hsp90 and enhances degradation of hsp90 client proteins (24, 25) . AKT is a hsp90 client protein, whose activity and, subsequently, expression are decreased after treatment with 17-AAG in vitro (26). Interestingly, As 2 O 3 and 17-AAG act synergistically to induce apoptosis of HL-60 and Jurkat cells (26) . We investigated whether As 2 O 3 enhanced 17-AAG -induced cytotoxicity in NB4 cells. As 2 O 3 (0.5 Amol/L), 17-AAG (0.125 or 0.25 Amol/L), and the combinations were used in 3-day growth curves to determine the effects of combination therapy. Indeed, the combination of As 2 O 3 with 17-AAG was significantly more inhibitory than either drug alone (Fig. 6A ). Higher concentrations of As 2 O 3 (1 Amol/L) also enhanced the efficacy of 17-AAG even at 24 h (data not shown). Total AKT levels also were assessed at 24 h using immunoblotting. As 2 O 3 and 17-AAG alone decreased total AKT levels, but the combination further decreased AKT expression ( Fig. 6B and C) . These data suggest that the enhanced cytotoxic effects of the combination treatment may be due to a decrease in prosurvival signals from AKT. 
Discussion
As 2 O 3 is used effectively to treat patients with APL and shows promise as a treatment for multiple myeloma and myelodysplastic syndrome. Understanding the mechanism by which As 2 O 3 induces apoptosis may identify potential targets for combination therapies and broaden the malignancies for which arsenic can provide effective treatment. Previous data from our laboratory and others show that generation of ROS and activation of the JNK signaling pathway mediate the arsenic-induced apoptotic signal in APL cells (4, 5, 8, 9) . Based on these data, we hypothesized that As 2 O 3 would inhibit negative regulators of this pathway.
Several laboratories have investigated a role for AKT in As 2 O 3 -induced death, although the data are confusing. In one report, pretreatment with inhibitors of phosphoinositide 3-kinase had no effect on As 2 O 3 -induced death in NB4 cells but enhanced the death in MOLT-4 T-cell leukemia line (27) . However, another report showed that a cotreatment with the same inhibitors enhances As 2 O 3 -induced apoptosis in NB4 cells but not the cytotoxicity associated with ionidamine, camptothecin, or cisplatin (28) . The cytotoxic effect is correlated with a decrease in phosphorylated AKT but not total AKT (28) . Our data show that cotreatment with phosphoinositide 3-kinase inhibitors can sensitize arsenic-resistant NB4 subclones (Fig. 3C ) and confirm that overexpression of a constitutively active AKT construct rescues cells from As 2 O 3 -induced apoptosis (Fig. 3D) . Of note, we also observed the As 2 O 3 -induced decrease of AKT protein in other cell lines, including several multiple myeloma lines and MDA-MB-468 breast cancer cells, which overexpress phosphorylated AKT (Fig. 2) . In addition to confirming an association between dominant-negative AKT and As 2 O 3 -induced JNK activation and apoptosis, we focused on the observed decrease in AKT total protein and show that As 2 O 3 does not decrease AKT transcription or translation (Supplementary Fig. S1 ) but causes decreased AKT protein expression that can be blocked by selective caspase inhibitors.
Several other apoptotic stimuli result in cleavage of AKT protein. Etoposide and Fas stimulation results in AKT cleavage in U937 and Jurkat cells (21) . Tumor necrosis factor-a treatment of adipocytes causes AKT cleavage, which can be inhibited by caspase inhibitors but not proteosome inhibitors (29) . Glucose deprivation -enhanced, tumor necrosis factor -related apoptosis-inducing ligandinduced cytotoxicity is associated with caspase-3 -mediated AKT cleavage (30) . Oxidative stress triggered by treatment with H 2 O 2 also resulted in proteolysis of AKT (23) . Cytokine withdrawal in 32D cells causes caspase-3 -mediated cleavage at the Asp 462 residue (31), but mutation of this residue did not alter the ability of As 2 O 3 to degrade AKT (data not shown). In addition, individual mutation of two other amino acids, previously shown to be important in AKT cleavage by caspases following death receptor activation (22) , had no effect on As 2 O 3 -mediated AKT protein decrease (data not shown). Interestingly, hsp90 inhibitors target AKT for degradation via the ubiquitinproteosome pathway (20) .
We show that AKT and JNK are inversely activated in response to As 2 O 3 . In addition, As 2 O 3 treatment decreases the association of AKT with JIP1, the scaffolding protein on which the MAPK cascade assembles. Despite several reports that AKT inhibits association of JNK with JIP1, it is unclear what triggers release of AKT from JIP1. Clearly, release occurs after As 2 O 3 treatment at a time before total AKT protein is degraded (Fig. 4B ). This suggests that release of AKT from the JIP1/JNK complex may be the initiating event that activates the JNK cascade leading to loss of AKT and induction of apoptosis.
Our data suggest that As 2 O 3 could be used in combination with new targeted agents to increase the cytotoxicity and therapeutic spectrum. This includes agents that decrease AKT activity or expression, such as 17-AAG ( Fig. 6) . Alternatively, it may be used to enhance other promising drugs that unexpectedly increase AKT. CCI-779 (temsirolimus) is a rapamycin derivative that targets mammalian target of rapamycin, which lies downstream of AKT signaling. CCI-779 effectively inhibits growth of tumor cells in vitro and in vivo but also results in an increase in activated AKT via an ill-defined feedback mechanism (32, 33) . Targeting the activated AKT by combining As 2 O 3 with CCI-779 may result in enhanced tumor killing. Malignancies where the tumor suppressor PTEN is often silenced and AKT signaling is constitutively activated, such as glioblastoma multiforme, prostate cancer, endometrial cancer (34) , and Herceptin-resistant breast cancer (35) , are being targeted in clinical trials with mammalian target of rapamycin inhibitors. The combination of As 2 O 3 and mammalian target of rapamycin inhibitors in these tumor settings is particularly intriguing and is currently under investigation in our laboratory.
